Scribe Therapeutics Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SCTX | EDIT | PRQR | NTLA | DTIL | CRSP | |
|---|---|---|---|---|---|---|
| Market cap | 317.67M | 417.74M | 198.98M | 1.72B | 226.84M | 5.02B |
| P/E (TTM) | — | — | — | — | 32.5 | — |
| Forward P/E | -4.6 | -3.6 | -3.0 | -4.8 | -4.4 | -14.4 |
| Price/book | -0.3 | 4.0 | 2.2 | 2.4 | 4.4 | 3.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −14.60% | −6.47% | −42.44% | −12.60% | +5.29% | −12.28% |
| Today | +3.58% | +4.62% | +2.92% | +3.79% | +16.50% | +3.57% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SCTX news ›Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Has Consensus Price Target of $51.75
Posted by Defense World Staff on Oct 26th, 2026 Read Our Latest Analysis on SCTX Scribe Therapeutics is a biotechnology company focused on developing CRISPR-based genetic medicines. The company’s platform is designed to engineer CRISPR…
Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst
Seeking Alpha - Scribe Therapeutics is initiated with a buy rating, targeting the in-vivo gene therapy market for cardiometabolic diseases with lead asset STX-1150. - STX-1150 aims to provide durable, reversible P
Why Did Scribe Therapeutics (NASDAQ:SCTX) Fall 7% to USD 19.22?
Explore 3 Stock Ideas & Industry Insights Download Free Report A Light Volume Decline Risks for Early Gene Editing Companies A:No catalyst was found. The stock gapped down 1.89%, fell 5.08% from the open and traded 79,699 shares, about 0.1…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net1
- kalkine.ca1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.